Clinical Trial Update: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) [Phase 3]

View source ↗

Summary

The Phase 3 trial RASolve 301 evaluating daraxonrasib (RMC-6236) for RAS-mutated non-small cell lung cancer is currently recruiting. No results are reported yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Daraxonrasib

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING